Search

Displaying results 1781 - 1790 of 6074 in total
  1. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. … to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for

  2. Drug

    Nitrite

    go.drugbank.com/drugs/DB12529
    ApprovedWithdrawn

    Nitrite is under investigation for the treatment of Heart Failure.

  3. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies.

  4. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.

  5. Drug

    Levonorgestrel

    go.drugbank.com/drugs/DB00367
    ApprovedInvestigational

    Levonorgestrel (LNG) is a synthetic progestogen similar to Progesterone used in contraception and hormone therapy. Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released fr...

    Categories: Hormonal Contraceptives for Systemic Use
  6. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]

  8. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione has been investigated for the treatment of Blood Coagulation Disorders. … Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

  9. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). … Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.

  10. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist